Live Breaking News & Updates on Esperion Therapeutic

Stay updated with breaking news from Esperion therapeutic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Esperion Therapeutics' (ESPR) "Buy" Rating Reiterated at HC Wainwright

Esperion Therapeutics' (ESPR) "Buy" Rating Reiterated at HC Wainwright
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

Esperion Therapeutics Company Profile , Vanguard Group Inc , Esperion Therapeutics Inc , Armistice Capital , Capital Partners , Needham Company , Esperion Therapeutics , Free Report , Esperion Therapeutic , Moderate Buy , Get Free Report , Asset Management , Wasatch Advisors , Esperion Therapeutics Daily ,

Q1 2026 Earnings Estimate for Esperion Therapeutics, Inc. Issued By Zacks Research (NASDAQ:ESPR)

Q1 2026 Earnings Estimate for Esperion Therapeutics, Inc. Issued By Zacks Research (NASDAQ:ESPR)
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

Zacks Research , Needham Company , Esperion Therapeutics Inc , Esperion Therapeutics Company Profile , Connor Clark Lunn Investment Management Ltd , Armistice Capital , Capital Partners , Esperion Therapeutics , Free Report , Esperion Therapeutic , Therapeutics Stock Down , Get Free Report , Asset Management , Connor Clark , Lunn Investment Management , Esperion Therapeutics Daily ,

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Expected to Earn FY2026 Earnings of $1.44 Per Share

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Expected to Earn FY2026 Earnings of $1.44 Per Share
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United States , Esperion Therapeutics Company Profile , Portfolio Partners , Herbst Group , Chicago Partners Investment Group , Zacks Research , Needham Company , Simplicity Wealth , Esperion Therapeutics Inc , Esperion Therapeutics , Free Report , Esperion Therapeutic , Get Free Report , Partners Investment Group , Esperion Therapeutics Daily ,

Q4 2025 Earnings Forecast for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Issued By Zacks Research

Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Investment analysts at Zacks Research cut their Q4 2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued on Monday, April 29th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will earn $0.14 per share for the quarter, […] ....

United States , Esperion Therapeutics Inc , Simplicity Solutions , Connor Clark Lunn Investment Management Ltd , Esperion Therapeutics Company Profile , Zacks Research , Capital Partners , Needham Company , Pinnacle Associates Ltd , Esperion Therapeutics , Free Report , Esperion Therapeutic , Get Free Report , Lunn Investment Management , Pinnacle Associates , Esperion Therapeutics Daily , Nasdaq Espr , Earnings Estimates ,

HC Wainwright Reaffirms "Buy" Rating for Esperion Therapeutics (NASDAQ:ESPR)

HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research report sent to investors on Monday morning, Benzinga reports. They currently have a $16.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Esperion Therapeutics’ FY2026 earnings at $2.50 EPS, FY2027 earnings at […] ....

United States , Esperion Therapeutics Inc , Royal Bank , Prelude Capital Management , Barclays Plc , Needham Company , Capital Partners , Vanguard Group Inc , Esperion Therapeutics , Free Report , Esperion Therapeutic , Get Free Report , Capital Management , Esperion Therapeutics Daily , Nasdaq Espr , Reiterated Rating , Hc Wainwright ,